| アブストラクト | BACKGROUND AND AIMS: Real-world evidence on treatment of hyperlipidaemia (HLD) in Japan is limited. We aimed to describe treatment patterns, persistence with, and adherence to treatment in Japanese patients with HLD. METHODS: Retrospective analyses of adult HLD patients receiving drug therapy in 2014-2015 were conducted using the Japan Medical Data Center (JMDC) and Medical Data Vision (MDV) databases. Depending on their HLD treatment history, individuals were categorised as untreated (UT) or previously treated (PT), and were followed for at least 12 months. Outcomes of interest included prescribing patterns of HLD drug classes, persistence with treatment at 12 months, and adherence to treatment. RESULTS: Data for 49,582 and 53,865 patients from the JMDC and MDV databases, respectively, were analysed. First-line HLD prescriptions for UT patients were predominantly for moderate statins (JMDC: 75.9%, MDV: 77.0%). PT patients most commonly received combination therapy (JMDC: 43.9%, MDV: 52.6%). Approximately half of the UT patients discontinued treatment during observation. Within each cohort, persistence rates were lower in UT patients than in PT patients (JMDC: 45.0% vs. 77.5%; MDV: 51.9% vs. 85.3%). Adherence was >/=80% across almost all HLD drug classes, and was slightly lower in the JMDC cohort than MDV cohort. CONCLUSIONS: Most common prescriptions were moderate statins in UT patients and combination therapy in PT patients. The high discontinuation rate of HLD therapy in UT patients warrants further investigation and identification of methods to encourage and support long-term persistence. |
|---|
| ジャーナル名 | Atherosclerosis |
|---|
| Pubmed追加日 | 2018/4/1 |
|---|
| 投稿者 | Wake, Mayumi; Onishi, Yoshie; Guelfucci, Florent; Oh, Akinori; Hiroi, Shinzo; Shimasaki, Yukio; Teramoto, Tamio |
|---|
| 組織名 | Japan Medical Affairs, Takeda Pharmaceutical Company Limited, Tokyo, Japan.;Creativ-Ceutical K.K., Tokyo, Japan.;Creativ-Ceutical, Paris, France.;Teikyo Academic Research Center, Teikyo University, Tokyo, Japan. Electronic;address: ttera@med.teikyo-u.ac.jp. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/29604481/ |
|---|
